Diabetes News

Metabolic dysfunction-associated steatotic liver disease affects more than one-third of the world’s population and is associated with significant clinical and economic burden, as well as impairment of health-related quality of life.

To put it simply, diabetes and steatotic liver disease are joined at the hip. They are part of the same biological process that involves multiple organs, connected by the concept of metabolic flexibility — or lack thereof.

Metabolic dysfunction-associated steatohepatitis is significantly more common in patients with type 2 diabetes, and most patients with MASH — formerly known as NASH — experience metabolic abnormalities, including obesity.

Metabolic dysfunction-associated steatotic liver disease is a public health threat, affecting 30% to 38% of the adult population globally. The prevalence has risen in parallel with epidemics of obesity and type 2 diabetes.

Millions of dollars have been spent trying to find medications that could treat this complex disorder. The focus has been on drugs for more severe disease, as it leads to complications, and early stages have been somewhat ignored.

People who delayed diabetes through diet and exercise for at least 4 years after their prediabetes diagnosis had a lower risk for death and other adverse outcomes vs. those who were diagnosed with diabetes during that time, a study showed.

Combined SGLT2 inhibitor and GLP-1 receptor agonist therapy could provide additional cardiovascular and renal benefits for adults with type 2 diabetes, according to data from a meta-analysis published in The Lancet Diabetes & Endocrinology.

The FDA declined to approve once-weekly basal insulin icodec for the treatment of diabetes and is requesting more information from Novo Nordisk, according to a company press release.

Circulating levels of some microRNA species may predict response to diabetes treatment and changes in beta-cell function among children and adolescents with type 2 diabetes, according to findings from the TODAY study.

More than one in five adults in the U.S. with type 1 diabetes also have chronic kidney disease, according to findings from a brief report published in Diabetes Care.